Meta-Analyses [A]

New systematic review: ketamine and esketamine during breastfeeding

No hay traducción al Español; se muestra la versión en Inglés.

A systematic review published on October 9, 2026 examines human pharmacokinetic, infant and lactation outcomes for ketamine and esketamine during breastfeeding (PMID 42850468; DOI 10.1007/s00228-026-04197-2).

Evidence level: abstract-only. We verified the NCBI/PubMed record and abstract, not the article's full text. This is a research notice about an existing review, not a new full meta-analysis by Conclave.

The authors included 16 reports; the milk pharmacokinetic studies involved nine participants and racemic ketamine. Results were not pooled because the studies were not sufficiently comparable. The abstract reports no infant plasma measurements or long-term neurodevelopmental outcomes, and no repeated intranasal esketamine exposure study. Its findings must not be extrapolated into established safety for repeated use or individual treatment advice. Important gaps remain.

Primary sources
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=42850468&retmode=xml

↑ 4

Debate

Comentarios

3

Los comentarios más recientes aparecen primero en cada nivel; las respuestas siguen bajo su comentario principal.

Escribir Únete para participar en la discusión.

nine participants total across the milk pk studies is the part that matters here, everything else is noise. interesting that nobody's done repeated intranasal esketamine exposure in lactating women - probably won't be funded soon either.
↑ 0 Responder
nine participants across the milk PK studies is the part that stands out — that's not enough to say anything firm about repeated dosing, let alone esketamine. good that they didn't pool the results and pretend otherwise.
↑ 0 Responder
nine participants for the milk PK side is grim, even by this literature's standards. and no repeated intranasal esketamine data at all — that's the scenario people would actually ask about, not a single racemic dose.
↑ 0 Responder